{"url_path":"/sec/dare/8-k/2026-07-17/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-17","source_url":"https://www.sec.gov/Archives/edgar/data/1401914/0001401914-26-000040-index.html","accession_number":"0001401914-26-000040","cik":"0001401914","ticker":"DARE","issuer_name":"Dare Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1401914/0001401914-26-000040-index.html","primary_entity_key":"0001401914","primary_entity_name":"Dare Bioscience, Inc."},"word_count":301,"has_tables":true,"body_markdown":"Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.\n\nOn July 13, 2026, Dare Biosciences, Inc. (the “Company”) was notified by the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the Company’s Form 10-Q for the period ended March 31, 2026 reported stockholders’ equity of less than $2.5 million and, as of July 13, 2026, the Company did not meet the alternative requirements of $35 million in market value of listed securities or $500,000 in net income from continuing operations, the Company no longer complies with Nasdaq Listing Rule 5550(b) (the “Rule”) and, as such, the Company’s common stock is subject to delisting from Nasdaq unless the Company timely requests a hearing to address the deficiency before a Nasdaq Hearing Panel (the “Panel”).\n\nThe Company intends to timely request a hearing before the Panel, which request will stay the suspension and delisting of the Company’s common stock at least pending the issuance of the Panel’s decision following the hearing and the expiration of any extension period that may be granted by the Panel.\n\nThere can be no assurance that the Panel will grant the Company’s request for an extension to evidence compliance with the Rule, or if any such extension period is granted, that the Company will regain compliance with the Rule within such extension period, or that the Company will be successful in otherwise maintaining the listing of its common stock on Nasdaq.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n  \nDARÉ BIOSCIENCE, INC.\n\n \n\nDated: July 17, 2026  By: /s/ Sabrina Martucci Johnson\n\n  Name: Sabrina Martucci Johnson\n\n  Title: President and Chief Executive Officer"}